{"id":22725,"date":"2017-08-04T15:09:00","date_gmt":"2017-08-04T19:09:00","guid":{"rendered":"https:\/\/textiles.ncsu.edu\/news\/?p=22725"},"modified":"2024-05-17T09:50:12","modified_gmt":"2024-05-17T13:50:12","slug":"bite-resistant-clothing-cif","status":"publish","type":"post","link":"https:\/\/textiles.ncsu.edu\/news\/2017\/08\/bite-resistant-clothing-cif\/","title":{"rendered":"Textiles Leads Team Developing Bite-Resistant Clothing for Pregnant Women"},"content":{"rendered":"\n\n\n\n\n
Five promising North Carolina State University projects will receive support from the Chancellor\u2019s Innovation Fund (CIF), which helps NC State researchers move their inventions into the marketplace.<\/p>\n\n\n\n
\u201cNC State is establishing itself as a leader in technology commercialization,\u201d says Kelly Sexton, assistant vice chancellor for NC State\u2019s Office of Technology Commercialization and New Ventures. \u201cThis has been confirmed in recent reports by the Milken Institute and the Association of University Technology Managers listing NC State in the top 10 universities in the United States for technology licensing.\u201d<\/p>\n\n\n\n
NC State established the CIF program in 2010 with support from Chancellor Randy Woodson. Funding allows researchers to build on promising work with market potential.<\/p>\n\n\n\n
To date, CIF has granted a total of $2 million to 35 projects, which have attracted more than $12 million in follow-on research funding. Funded projects have generated 12 start-up companies, 17 license agreements and more than $1 million in licensing revenue.<\/p>\n\n\n\n
CIF\u2019s 2018 awardees are pursuing technologies that range from new anti-allergy therapies and potent anti-microbial agents to a complex virtual marine ecosystem modeling platform.<\/p>\n\n\n\n
Allergy Therapies for Companion Animals<\/strong><\/p>\n\n\n\n Pathobiologist Bruce Hammerberg and clinician Dr. Thierry Olivry from NC State\u2019s College of Veterinary Medicine have developed a potentially groundbreaking preventative allergy therapy for dogs.<\/p>\n\n\n\n Allergic diseases are among the most common reasons for canine and feline veterinary visits. According to the American Animal Hospital Association these diseases afflict an estimated 10 to 15 percent of pets under veterinary care. Current treatments vary in their effectiveness and have significant side effects, including the development or worsening of bacterial skin infections and a general loss of energy. Allergic diseases result from sensitization to environmental and food allergens. Sensitization requires that so-called IgE antibodies attach to inflammatory cells. Inflammatory cells with IgE on their surface discharge inflammatory mediators in the presence of allergens, causing the symptoms of an allergic reaction. Olivry and Hammerberg have designed and produced a novel protein that removes and blocks IgE from cells responsible for IgE-dependent allergic reactions. The CIF award will go toward a clinical trial of the new treatment in allergic dogs.<\/p>\n\n\n\n